Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Empirical Finance LLC

Empirical Finance LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 17.0% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,733 shares of the life sciences company’s stock after purchasing an additional 252 shares during the period. Empirical Finance LLC’s holdings in Illumina were worth $820,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ILMN. Baillie Gifford & Co. grew its stake in shares of Illumina by 8.1% in the 1st quarter. Baillie Gifford & Co. now owns 21,433,335 shares of the life sciences company’s stock valued at $8,231,687,000 after buying an additional 1,598,573 shares during the period. Ownership Capital B.V. grew its stake in shares of Illumina by 109.3% in the 1st quarter. Ownership Capital B.V. now owns 1,004,945 shares of the life sciences company’s stock valued at $385,959,000 after buying an additional 524,907 shares during the period. Veritas Asset Management LLP grew its stake in shares of Illumina by 77.9% in the 1st quarter. Veritas Asset Management LLP now owns 544,135 shares of the life sciences company’s stock valued at $208,980,000 after buying an additional 238,281 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Illumina by 53.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 433,801 shares of the life sciences company’s stock valued at $166,606,000 after buying an additional 151,703 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in shares of Illumina in the 1st quarter valued at approximately $52,431,000. 88.56% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:ILMN opened at $448.85 on Wednesday. The company has a market cap of $65.85 billion, a price-to-earnings ratio of 85.99, a PEG ratio of 2.24 and a beta of 0.91. The firm’s 50-day simple moving average is $482.60 and its 200-day simple moving average is $438.65. The company has a quick ratio of 5.64, a current ratio of 6.08 and a debt-to-equity ratio of 0.32. Illumina, Inc. has a fifty-two week low of $260.42 and a fifty-two week high of $555.77.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, August 5th. The life sciences company reported $1.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.36 by $0.51. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.01 billion. Illumina had a net margin of 19.36% and a return on equity of 18.12%. During the same quarter in the previous year, the firm earned $0.62 earnings per share. On average, research analysts forecast that Illumina, Inc. will post 6.48 EPS for the current year.

In other Illumina news, SVP Susan H. Tousi sold 1,000 shares of Illumina stock in a transaction dated Wednesday, August 4th. The shares were sold at an average price of $500.00, for a total transaction of $500,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Charles Dadswell sold 314 shares of the business’s stock in a transaction that occurred on Monday, August 23rd. The shares were sold at an average price of $489.10, for a total transaction of $153,577.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,881 shares of company stock worth $1,873,334. 0.23% of the stock is owned by insiders.

A number of research firms recently weighed in on ILMN. Piper Sandler increased their price objective on shares of Illumina from $510.00 to $560.00 and gave the stock an “overweight” rating in a research report on Friday, August 6th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $504.00 price objective for the company in a research report on Wednesday, June 30th. Robert W. Baird reaffirmed a “hold” rating on shares of Illumina in a research report on Sunday, August 22nd. Barclays increased their target price on shares of Illumina from $355.00 to $365.00 and gave the stock an “underweight” rating in a report on Friday, August 6th. Finally, Canaccord Genuity increased their target price on shares of Illumina from $515.00 to $555.00 and gave the stock a “buy” rating in a report on Monday, August 9th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $392.06.

Illumina Company Profile

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

Read More: What is a management fee?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.